In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their ...

CHICAGO — GLP-1, or Glucagon-like peptide-1, medications, similar to Ozemppic and Wegovy, are becoming more accessible, and ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

(Wegovy is the version of semaglutide that’s available in the UK.) But tirzepatide (Mounjaro) has since been shown to pack more of a punch. “Semaglutide contains just one molecule, GLP-1 ...

Elected officials are looking to expand access to weight loss drugs like Ozempic and Wegovy for low-income Virginians as part ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...

In terms of its financial performance, Novo Nordisk's bread and butter are its therapies for type 2 diabetes (Ozempic) and obesity (Wegovy); both are the same molecule, semaglutide, which works by ...